Single-agent clinical studies have shown that even the molecule obatoclax, which inhibits both BCL2 as well as its related apoptosis regulator MCL1, is alone not effective in AML, apparently due to the diversity of antiapoptotic mechanisms that AML cells may employ [138]. The gene discussed is BCL2; the disease is acute myeloid leukemia.